Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea Toughens Corporate Disclosure Rules To Improve R&D Transparency

Executive Summary

Amid a recent stock price rigging scandal involving a local bioventure, and the global push to improve the transparency of clinical trials, Korean financial authorities are pushing for improved public disclose by pharma/biotech companies of key information on clinical development, such as trial failures or suspensions, to better inform investors. 

Related Content

Korea 2018 Review: Hopes And Worries Coexist In Pharma Sector
Biosimilar Firms Main Beneficiaries Of Korea R&D Cost Accounting Changes?
Nature Cell Mired In Uncertainty as CEO Arrested For Alleged Stock Price Manipulation
Why The EU’s New Clinical Trials System Is Taking So Long
Korea To Examine Companies' R&D-Related Accounting For Transparency
Clinical Study Disclosures Will Make Drug Reviews More Efficient – Gottlieb





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts